Robinhood Asset Management Boosts ResMed Stake
Robinhood Asset Management LLC has acquired a new stake of 2,622 shares in ResMed Inc. (NYSE:RMD), a medical equipment provider specializing in sleep apnea and respiratory care devices. This investment, valued at approximately $632,000, signals Robinhood's confidence in ResMed's growth potential and market position within an industry experiencing increased demand for sleep disorder treatments. The hedge fund focuses on emerging growth opportunities, and ResMed's strong sales of CPAP machines contribute to its appeal.
Rathbones Group PLC Sells 18,632 Shares of DexCom, Inc. $DXCM
Rathbones Group PLC reduced its stake in DexCom, Inc. by 13.5%, selling 18,632 shares and retaining 119,891 shares valued at approximately $7.96 million. This divestment follows DexCom's strong quarterly earnings, which beat analyst estimates with $0.68 EPS and $1.26 billion in revenue, representing a 13.1% year-over-year increase. Analysts maintain a "Moderate Buy" rating for DXCM with an average price target of $86.50.
Diabetes device recall surge reveals a worrying information gap
The article highlights a significant increase in diabetes device recalls, particularly for continuous glucose monitors (CGM) and insulin pumps, indicating a growing problem in the medical device industry. This surge in recalls suggests a concerning information gap related to the safety and efficacy of these essential medical devices. The report mentions specific Class I and Class II recalls in 2025 involving major companies like Abbott Laboratories, Tandem Diabetes Care, Dexcom, Medtronic, and Insulet Corp.
DexCom Inc. stock outperforms competitors on strong trading day
DexCom Inc. (DXCM) shares rose 1.59% to $63.21 on Monday, breaking a two-day losing streak, while the S&P 500 Index and Dow Jones Industrial Average also saw gains. This performance marked a strong trading day for DexCom Inc., outperforming the broader market.
Nisa Investment Advisors Reduces Neurocrine Biosciences Stake
Nisa Investment Advisors LLC significantly reduced its holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 80.8% in the fourth quarter of 2025, selling 21,945 shares. The institutional investor now owns 5,201 shares worth approximately $738,000. While the specific reasons for this portfolio adjustment were not disclosed, it could indicate a shift in investor sentiment or strategy concerning the biopharmaceutical company's future.
Aberdeen Group plc Acquires 43,990 Shares of DexCom, Inc. $DXCM
Aberdeen Group plc significantly increased its stake in DexCom, Inc. by 9% in Q4, acquiring 43,990 additional shares and bringing its total holdings to 530,363 shares valued at approximately $35.2 million. DexCom, a medical device company specializing in continuous glucose monitoring, recently surpassed quarterly earnings and revenue estimates. The stock currently holds a "Moderate Buy" rating from analysts with an average price target of $86.50.
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against DexCom, Inc. (DXCM) and Encourages Shareholders to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC has initiated an investigation into DexCom, Inc. (DXCM) regarding potential corporate wrongdoing. The firm is encouraging shareholders who purchased DexCom securities before January 8, 2024, and still hold them, to join the investigation. The firm operates on a contingency fee basis, aiming to recover investor capital and ensure corporate accountability.
TD Cowen reiterates DexCom stock Buy rating on margin expansion outlook
TD Cowen has reiterated a Buy rating on DexCom Inc. (NASDAQ:DXCM) stock, setting an $84.00 price target, aligning with InvestingPro’s Fair Value, suggesting the stock is undervalued. The firm raised its estimates for 2026-2028, anticipating significant gross and operating margin expansion, while acknowledging recent concerns about a slowing U.S. continuous glucose monitoring market. DexCom recently surpassed Q4 2025 earnings and revenue expectations, and other firms like Evercore ISI, Canaccord Genuity, and Stifel have also issued positive ratings or adjusted price targets, with a Google executive appointed to its board.
Banque Pictet & Cie SA Raises Stock Holdings in DexCom, Inc. $DXCM
Banque Pictet & Cie SA significantly increased its stake in DexCom, Inc. (NASDAQ:DXCM) by 58.2% in Q4, acquiring an additional 40,411 shares for a total holding worth $7.29 million. This move comes as DexCom reported strong quarterly earnings, beating analyst estimates with $0.68 EPS and $1.26 billion in revenue. Analysts currently rate DexCom as a "Moderate Buy" with a consensus price target of $86.50.
DexCom, Inc. (NASDAQ:DXCM) Receives Consensus Rating of "Moderate Buy" from Analysts
DexCom, Inc. (NASDAQ:DXCM) has received a consensus "Moderate Buy" rating from twenty-four analysts, with an average 12-month price target of $86.50. Recent analyst actions include price target adjustments and reiterated ratings, generally positive. The company reported strong Q4 earnings, exceeding estimates, and institutional investors have been actively trading shares.
Align Technology, QuidelOrtho, DexCom, Insulet, and Omnicell shares are falling, what you need to know
This article indicates that shares of Align Technology, QuidelOrtho, DexCom, Insulet, and Omnicell are currently experiencing a decline. The title suggests that the content would provide an explanation for these drops, but the article text itself is not provided.
TD Cowen reiterates DexCom stock Buy rating on margin expansion outlook
TD Cowen has reiterated a Buy rating on DexCom (NASDAQ:DXCM) stock, setting an $84.00 price target, aligning with InvestingPro’s Fair Value. The firm raised its estimates for 2026-2028, anticipating significant margin expansion, despite recent concerns about a slowdown in the U.S. continuous glucose monitoring market. DexCom recently surpassed Q4 2025 earnings and revenue expectations, and other analysts like Evercore ISI and Stifel also maintain optimistic ratings.
TD Cowen reiterates DexCom stock Buy rating on margin expansion outlook
TD Cowen has reiterated a Buy rating on DexCom Inc. (NASDAQ:DXCM) stock with an $84.00 price target, citing strong margin expansion prospects for 2026-2028. The firm raised its estimates based on these profitability improvements and believes in a reacceleration of the U.S. continuous glucose monitoring market. This outlook comes despite recent concerns about market slowing and follows DexCom's strong fourth-quarter 2025 earnings report which surpassed analyst expectations.
Dexcom Schedules First Quarter 2026 Earnings Release and Conference Call for April 30, 2026 at 4:30 p.m. Eastern Time
DexCom, Inc. (NASDAQ:DXCM) announced its plans to release first-quarter 2026 financial results after market close on Thursday, April 30, 2026. A conference call will follow at 4:30 p.m. Eastern Time to review the company's performance, with a concurrent webcast available on Dexcom's investor relations website. Interested parties can dial in using the provided numbers and confirmation ID.
Integer to release Q1 results April 30 before 8 a.m. CT webcast
Integer Holdings Corporation will webcast its first-quarter 2026 financial results conference call on Thursday, April 30, 2026, at 8 a.m. CT (9 a.m. ET). The company plans to release its financial results via news release earlier that day. Investors can find dial-in information and a webcast registration link on Integer's Investor Relations website, with an audio replay available for seven days.
SWS Partners Has $3.69 Million Stake in DexCom, Inc. $DXCM
SWS Partners increased its stake in DexCom, Inc. (NASDAQ:DXCM) by 45.8% in the fourth quarter, now owning 55,560 shares valued at approximately $3.69 million. DexCom reported strong Q4 results, surpassing earnings and revenue estimates, and maintains a "Moderate Buy" consensus rating from analysts with an average price target of $86.50. Institutional investors hold a significant 97.75% of the company's stock.
Compagnie Lombard Odier SCmA Grows Holdings in DexCom, Inc. $DXCM
Compagnie Lombard Odier SCmA increased its stake in DexCom, Inc. by 18.9% in the fourth quarter of 2025, now holding 216,798 shares valued at approximately $14.39 million. DexCom surpassed Q4 earnings and revenue expectations, reporting EPS of $0.68 and revenue of $1.26 billion, up 13.1% year-over-year. The company maintains a "Moderate Buy" consensus rating from Wall Street analysts with an average price target of $86.50.
Diabetes Focused MiniMed Recovery Story Builds As Pipeline Improves
William Blair initiated coverage on MiniMed Group Inc. (NASDAQ: MMED), highlighting its recovery story despite past competitive setbacks. The company, a unit of Medtronic Plc, is improving its product pipeline with new innovations like the MiniMed Flex, a next-generation insulin pump cleared by the FDA. Despite facing ongoing competition and profitability challenges, its valuation presents an attractive risk-reward profile for investors.
Medtronic plc Stock: Navigating Transformation and Growth in MedTech Amid Analyst Shifts
Medtronic plc is undergoing a significant transformation, including a planned spinoff of its MiniMed diabetes business, and reported strong Q3 FY2026 results with revenue of $9.02 billion. The company is focused on high-margin therapies and boasts a robust dividend policy, approaching Dividend King status. While analysts show mixed views, with Barclays raising its target to $120, execution risks related to the spinoff and competitive pressures remain key areas for investors to monitor.
Equity plan expansion at DiaMedica (NASDAQ: DMAC) adds 3.5M shares
DiaMedica Therapeutics Inc. (NASDAQ: DMAC) is proposing to expand its 2019 Omnibus Incentive Plan by adding 3.5 million shares, increasing the total authorized shares to 10.5 million, and extending the plan's term by ten years. This proposal will be voted on at the annual shareholder meeting on May 20, 2026, alongside the election of directors, ratification of Baker Tilly US, LLP as auditors, and an advisory vote on executive compensation. The company states the expansion is crucial for attracting, motivating, and retaining talent and aligns with its pay-for-performance compensation philosophy.
Insulet Corporation Trade Ideas — MIL:1PODD
This article compiles various trade ideas and technical/fundamental analyses for Insulet Corporation (1PODD, NASDAQ:PODD). Analysts offer diverse perspectives, including long positions based on strong earnings, technical breakouts like "cup with handle" formations, and potential gap fills, alongside a bearish signal. The company's fundamentals, such as high EPS and sales growth, and a significant insider buy are highlighted.
Segmentation, Major Trends, and Competitive Dynamics in the Insulin Patch Pumps Market
The global insulin patch pumps market is projected to reach $2.55 billion by 2030, growing at a CAGR of 10.2%, driven by advancements in diabetes care technology and increased adoption of closed-loop systems. Key players like Insulet Corporation and Medtronic PLC are innovating with products like the Embecta insulin patch pump, which recently received FDA clearance. The market is segmented by type (reusable, disposable, smart, automated), mode (basal, bolus), and application (Type 1 and Type 2 diabetes), reflecting diverse patient needs and technological progress.
Bronstein, Gewirtz & Grossman, LLC Encourages DexCom, Inc. (DXCM) Stockholders to Inquire about Securities Investigation
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against DexCom, Inc. (DXCM) on behalf of investors who purchased securities prior to January 8, 2024, and still hold them. The investigation focuses on whether DexCom and its officers engaged in corporate wrongdoing. The firm encourages affected stockholders to inquire about assisting the investigation at no cost.
Pallas Capital Advisors LLC Decreases Stock Holdings in DexCom, Inc. $DXCM
Pallas Capital Advisors LLC significantly reduced its stake in DexCom, Inc. (NASDAQ:DXCM) by 69.7% in the fourth quarter, selling 16,243 shares and retaining 7,055 shares valued at $468,000. Despite this, institutional ownership remains very high at 97.75%, with Vanguard Group Inc. being a major holder. DexCom recently reported strong earnings, exceeding analyst expectations with a 13.1% increase in revenue, and has a "Moderate Buy" consensus rating from analysts.
DexCom Inc. stock rises Tuesday, still underperforms market
Shares of DexCom Inc. (DXCM) rose 1.45% to $62.80 on Tuesday, breaking a three-day losing streak, despite the broader market also experiencing a strong trading session. The company's stock still underperformed the S&P 500 Index, which gained 2.91%, and the Dow Jones Industrial Average, which rose 2.49%.
DexCom, Inc. Experiences Revision in Stock Evaluation Amid Market Pressures
DexCom, Inc. has seen a recent decline in its stock price, dropping to $62.25 from a close of $66.09, amidst broader market pressures and bearish technical indicators. While the company's performance over the last year and three years significantly lags behind the S&P 500, it has shown strong resilience and outperformance over a ten-year period. This mixed performance suggests potential for recovery despite current short-term challenges.
Earnings Beat: Can Oak Woods Acquisition Corporation Equity Warrant maintain sales growth - Share Buyback & Reliable Breakout Stock Forecasts
This article poses a question about Oak Woods Acquisition Corporation Equity Warrant's sales growth and includes sections on share buybacks and stock forecasts. However, the majority of the content discusses unrelated topics, such as Lee Kang-in's apology and former Taiwanese President Ma Ying-jeou's visit to mainland China, framed around a recurring speculative investment prompt regarding "NEPH." It also contains numerous financial market-related questions about various company stocks that are not directly addressed.
DexCom Inc (DXCM) Stock Price Down 5.81% on Mar 30
Shares of DexCom Inc (DXCM) fell 5.81% on March 30, closing at $62.24 after reaching an intraday low of $61.99. Wall Street analysts have an average target price of $87.68 for DXCM, implying a 40.87% upside, with a consensus "Outperform" rating. GuruFocus estimates the fair value (GF Value) to be $123.16, suggesting a potential 97.88% upside.
Studies found frequent arrhythmias in diabetes, kidney and obesity patients
iRhythm Holdings (IRTC) announced new data from retrospective analyses presented at ACC.26, demonstrating a high prevalence of clinically actionable arrhythmias in patients with cardiometabolic and kidney-metabolic (CKM) conditions, including diabetes and obesity. The studies, utilizing iRhythm's Zio ambulatory ECG portfolio, found arrhythmias in 48% of CKD patients and 47% of patients with both diabetes and CKD, and a significantly increased risk of atrial fibrillation with severe obesity. iRhythm also launched iRhythm Academy for clinician education and updated its MyZio app with Spanish language support, while emphasizing the company's leadership in scaling AI in cardiology.
Dexcom Inc. Stock: Leader in Continuous Glucose Monitoring Faces Evolving Diabetes Care Landscape
Dexcom Inc. continues to be a key innovator in continuous glucose monitoring (CGM) technology, vital for diabetes management in North America. The company's business model relies on its CGM platforms, including the G7 system, generating revenue from disposable sensors, transmitters, and receivers. Dexcom's market position is bolstered by its direct-to-consumer approach, strong integration with digital health tools, and expansion into over-the-counter sales, making it a valuable stock for investors seeking growth in the healthcare sector.
Goldman Sachs Initiates Coverage of DexCom (DXCM) with Buy Recommendation
Goldman Sachs has initiated coverage on DexCom (DXCM) with a Buy rating. This bullish outlook suggests the firm sees significant upside potential for the medical device company. Investors will likely watch DexCom's stock performance closely following this major analyst recommendation.
Precision Trading with Dexcom Inc. (DXCM) Risk Zones
This article analyzes Dexcom Inc. (DXCM) with a focus on risk zones for precision trading. It highlights weak sentiment across all time horizons, supporting a short bias, and presents an exceptional 52.1:1 risk-reward short setup. The analysis provides specific entry/target/stop-loss zones for position trading, momentum breakout, and risk hedging strategies, derived from AI models.
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against DexCom, Inc. (DXCM) and Encourages Investors to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC has launched an investigation into DexCom, Inc. (DXCM) concerning potential corporate wrongdoing by its officers and/or directors. The firm is encouraging investors who purchased DexCom securities before January 8, 2024, and still hold them, to join the investigation. Investors can find more information or assist by contacting the firm directly.
DAVENPORT & Co LLC Reduces Stake in DexCom, Inc.
DAVENPORT & Co LLC significantly reduced its stake in DexCom, Inc. by 66.9% in the fourth quarter of 2025, selling 56,862 shares and retaining 28,105 shares valued at $1.87 million. This move is detailed in their recent Form 13F filing and indicates a potential shift in the firm's investment outlook on the medical device company or broader market conditions. DexCom is a leading manufacturer of continuous glucose monitoring systems.
DXCM (DexCom) Earnings Power Value (EPV) : $11.42 (As of Dec25)
This article from GuruFocus.com details the Earnings Power Value (EPV) of DexCom (DXCM), finding it to be $11.42 as of December 25th. The analysis labels DXCM as "Significantly Undervalued" with a GF Score of 91/100, despite having 3 warning signs. The article explains the EPV methodology, which values a stock based on current free cash flow rather than speculative future projections.
DexCom Inc. stock underperforms Friday when compared to competitors
DexCom Inc. (DXCM) stock fell on Friday, lagging behind its competitors. The stock closed down 1.25% at $127.67, while competitors like Insulet Corp. (PODD) and Tandem Diabetes Care Inc. (TNDM) saw gains. The broader S&P 500 also increased, indicating a relative underperformance for DexCom.
Wealth Enhancement Advisory Services LLC Grows Stake in Marvell Technology, Inc. $MRVL
Wealth Enhancement Advisory Services LLC significantly increased its stake in Marvell Technology, Inc. during the fourth quarter, purchasing an additional 25,295 shares and bringing its total holdings to 91,667 shares valued at $8.05 million. Analysts maintain a "Moderate Buy" consensus rating for Marvell, with several firms raising their price targets, indicating a positive outlook for the semiconductor company. However, recent insider selling by the CEO and other executives, totaling nearly $7.85 million in the last 90 days, shows a decrease in insider ownership.
Align Technology, QuidelOrtho, DexCom, Insulet, and Omnicell Shares Are Falling, What You Need To Know
Several major stock indices, including the S&P 500 and Dow Jones Industrial Average, declined today due to escalating uncertainty surrounding the U.S.-Iran conflict and Trump administration policy deadlines, causing significant drops in various company shares. Specifically, Align Technology, QuidelOrtho, DexCom, Insulet, and Omnicell experienced notable share price decreases. The market's negative reaction to unpredictability was also reflected in a dip in consumer confidence, though such price drops can sometimes present buying opportunities for high-quality stocks.
Align Technology, QuidelOrtho, DexCom, Insulet, and Omnicell Shares Are Falling, What You Need To Know
Shares of Align Technology, QuidelOrtho, DexCom, Insulet, and Omnicell experienced significant drops due to market reactions to the escalating U.S.-Iran conflict and policy deadlines from the Trump administration, leading to increased uncertainty and a decline in consumer confidence. Align Technology, in particular, fell by 6.7%, though its shares have shown some volatility and a slight gain year-to-date. The article suggests that such market overreactions can present buying opportunities for high-quality stocks.
Why Is GlucoTrack Stock Soaring Friday? - GlucoTrack (NASDAQ:GCTK)
GlucoTrack (NASDAQ:GCTK) shares surged over 47% on Friday after the company announced its intention to file an Investigational Device Exemption (IDE) with the FDA in Q2 2026 for its continuous blood glucose monitoring (CBGM) technology. This follows successful first-in-human studies demonstrating high accuracy and safety with a Mean Absolute Relative Difference (MARD) of 7.7%, and positions the company to advance its implantable CBGM system for insulin-dependent individuals. The company has also established manufacturing and reimbursement strategies, and bolstered its intellectual property portfolio.
Brazil and Australia trials put Glucotrack on path to a U.S. diabetes study
Glucotrack (Nasdaq: GCTK) plans to file an Investigational Device Exemption (IDE) with the FDA in Q2 2026 for a U.S. clinical trial of its fully implantable continuous blood glucose monitoring (CBGM) system. This move follows successful 2025 milestones, including a 10-patient first-in-human study in Brazil that demonstrated high accuracy and no serious adverse events, an Australia feasibility study, and the granting of three U.S. patents. Despite this progress, the stock saw a negative market reaction, declining 7.08%.
DEXCOM YoY EBITDA Growth: 52.52% | Significantly Undervalued
This article analyzes DexCom Inc. (DXCM), highlighting its Year-over-Year EBITDA Growth of 52.52% as of December 2025. GuruFocus assesses DXCM with a GF Score of 91/100 and a GF Value of $108.11, indicating it is significantly undervalued compared to its current price of $62.83. Investors are cautioned to review three warning signs despite the positive growth and valuation.
Vanguard (DXCM) amendment shows 0 shares after internal realignment
The Vanguard Group filed an amended 13G stating it beneficially owns 0 shares of Dexcom Inc (DXCM) common stock, representing 0% of the class. This change is due to an internal realignment effective January 12, 2026, under SEC Release No. 34-39538, where certain Vanguard subsidiaries will now report beneficial ownership separately. The amendment clarifies that Vanguard itself no longer has, or is deemed to have, beneficial ownership over these securities, with individual subsidiaries expected to report their holdings disaggregated.
DexCom Inc. stock underperforms Thursday when compared to competitors
DexCom Inc. (DXCM) stock fell 1.12% to $66.09 on Thursday, underperforming the broader market. This drop ended a two-day winning streak, as the S&P 500 Index and Dow Jones Industrial Average also experienced significant declines.
Abbott Laboratories stock faces pipeline scrutiny amid diagnostics slowdown in Q1 2026
Abbott Laboratories is experiencing a slowdown in its core diagnostics segment, leading to investor scrutiny despite continued strong performance from its FreeStyle Libre diabetes care franchise and structural heart devices. The company's stock is testing key support levels as investor focus shifts from post-pandemic growth to sustainable organic drivers and the resilience of its established businesses like nutritionals. Challenges include moderating Libre growth in some markets, regulatory hurdles, and persistent diagnostics weakness, though the company's defensive profile and dividend history offer stability.
Unpacking Q4 Earnings: ResMed (NYSE:RMD) In The Context Of Other Patient Monitoring Stocks
This article analyzes Q4 earnings for ResMed (RMD) and other patient monitoring stocks, highlighting their performance, challenges, and future growth prospects. While the sector benefits from an aging population and digital health adoption, companies face high R&D costs and regulatory hurdles. ResMed, iRhythm, DexCom, and Insulet all reported strong Q4 revenues, though market reactions to their earnings varied, with most stocks experiencing a decline post-results.
Dexcom Edges Up on Institutional Buying as CGM Leader Trails $260M Volume Ranks 465th
Dexcom (DXCM) shares gained 1.00% on March 24, 2026, driven by significant institutional buying and strong financial performance. The company reported impressive Q4 earnings, exceeding EPS estimates, and analysts maintain a "Moderate Buy" rating with an average target of $85.50. Despite insider sales and high valuation, Dexcom's leadership in the continuous glucose monitoring market and expanding reach beyond insulin-dependent patients position it for continued growth.
Dexcom Inc. stock surges on Evercore ISI upgrade to Outperform amid CGM market expansion
Dexcom Inc. stock rallied after Evercore ISI upgraded its rating to Outperform, citing strong positioning in the fast-growing continuous glucose monitoring (CGM) market. The upgrade reflects optimism about sustained revenue growth, particularly with the success of Dexcom's G7 CGM system, and highlights the company's leadership in diabetes management technology. The article also discusses market dynamics in diabetes care, Dexcom's financial performance, and why US investors should consider the stock despite potential risks.
Dexcom Inc. stock surges on Evercore ISI upgrade to Outperform amid CGM market expansion
Dexcom Inc. stock rallied following an upgrade to Outperform by Evercore ISI, driven by the company's strong positioning in the rapidly growing continuous glucose monitoring (CGM) market. The upgrade highlights Dexcom's innovative diabetes care solutions, particularly its G7 CGM system, amid increasing global diabetes prevalence and healthcare trends favoring preventive monitoring. This positions Dexcom as a key player for investors looking into the booming medtech sector, despite facing potential risks from reimbursement policies and competitive pressures.
Dexcom Inc. stock surges on Evercore ISI upgrade to Outperform amid CGM market expansion
Dexcom Inc. stock surged after Evercore ISI upgraded its rating to Outperform, citing the company's strong position in the growing continuous glucose monitoring (CGM) market. The upgrade reflects optimism about Dexcom's robust product pipeline, particularly its G7 CGM system, and its market penetration in diabetes care solutions. This positive outlook is supported by rising global diabetes prevalence, increased insurance coverage for CGM, and strategic partnerships.
